ArticleFrontiers in oncology2025
Quantitative MRCP metrics as imaging biomarkers to differentiate benign from malignant bile duct obstructions.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Prognostic Utility of Quantitative Magnetic Resonance Cholangiopancreatography in Patients With PSC: A Systematic Review With Structured Evidence Synthesis.Journal of computer assisted tomographyPooled it
- Quantitative MRCP as Part of Primary Sclerosing Cholangitis Standard of Care in the National Health Service in England: A Feasibility Assessment Among Hepatologists.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cholangiocarcinoma (CCA) is a difficult-to-detect rare cancer with high mortality rate and management costs. If detected early, surgical resection carries a 35% 5-year survival rate; this decreases to <11% 1-year survival rate when detected at later stages. Quantitative magnetic resonance cholangiopancreatography (MRCP+) provides measurements of the biliary tree and has been noted in clinical guidelines as having prognostic utility. We sought to determine whether MRCP+ metrics could differentiate benign and malignant biliary obstructions. Method: In this retrospective study of 38 patients with biliary obstruction with histologic characterisation, 23 had malignant obstructions whilst 15 had benign obstructions. Patients underwent non-contrast and contrast MRCP alongside clinical assessment. Non-contrast MRCP images were post-processed with MRCP+. Mann-Whitney U test compared the metrics between groups. Diagnostic accuracy of MRCP+ markers (duct number and dimensions, biliary tree and gallbladder volume) to stratify benign from malignant biliary obstructions was assessed using the area under the receiver operating characteristic curve (AUC). Results: All bile duct metrics were significantly higher in malignant biliary obstruction (p<0.05). Of the metrics assessed, total biliary tree volume was the most clinically meaningful predictor of malignancy, with a volume of ≥25ml differentiating between the two populations. A biliary tree volume of 25ml had an AUC of 0.79 to stratify between benign and malignant obstructions. Conclusion: Quantitative MRCP metrics, particularly total biliary tree volume, are shown here to differentiate malignant (CCA) from benign obstructions. As current pathways require either contrast administration or ERCP, quantitative MRCP may be an objective, non-invasive tool to identify CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.